| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Emergent Biosolutions Inc. (EBS) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 14 sells. EBS is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 374.1K | $3.09M | - | |
| CEO | 305.4K | $2.52M | - | |
| VP | 202.2K | $1.67M | - | |
| VP | 185.6K | $1.53M | - | |
| VP | 162.1K | $1.34M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2015 | Labinger Barry | EVP, Biosciences Div. | Sell | 3,376 | $36.50 | $123,224.00 | -11.8% | |
| Nov 13, 2015 | El-Hibri Fuad | Chairman | Sale+OE | 13,013 | $36.50 | $474,974.50 | -0.7% | |
| Nov 12, 2015 | Labinger Barry | EVP, Biosciences Div. | Sale+OE | 36,126 | $35.64 | $1,287,585.64 | -23.0% | |
| Nov 9, 2015 | El-Hibri Fuad | Chairman | Sale+OE | 13,225 | $35.50 | $469,487.50 | -0.7% | |
| Nov 6, 2015 | El-Hibri Fuad | Chairman | Sale+OE | 13,450 | $34.50 | $464,025.00 | -0.7% | |
| Nov 3, 2015 | El-Hibri Fuad | Chairman | Sale+OE | 13,689 | $33.50 | $458,581.50 | -0.7% | |
| Sep 11, 2015 | Bailey Sue | Director | Sale+OE | 6,080 | $32.37 | $196,796.80 | -9.6% | |
| Aug 13, 2015 | Richard Ronald | Director | Sell | 4,922 | $36.00 | $177,192.00 | -26.4% | |
| Aug 13, 2015 | Joulwan George A | Director | Sale+OE | 7,200 | $34.72 | $249,984.00 | -27.0% | |
| Aug 10, 2015 | El-Hibri Fuad | Chairman | Sell | 30,000 | $35.50 | $1,065,000.00 | -1.6% |